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Opinion statement
Early secondary prevention trials of fish and omega-3 polyunsaturated fatty acid (PUFA)
capsules reported beneficial effects on cardiovascular disease (CVD) outcomes, including
all-cause mortality and sudden cardiac death. These clinical findings, as well as observa-
tional and experimental data, demonstrated that omega-3 PUFAs reduced the risk of
coronary outcomes and overall mortality and were the basis for recommendations made
in the early 2000s to increase omega-3 PUFA intake. In the last 6 years, however, results
from both primary and secondary prevention trials have generally failed to show a
beneficial effect of omega-3 PUFA supplementation, bringing current recommendations
into question. Several possible reasons for these null findings have been proposed,
including short treatment periods, relatively low doses of omega-3 PUFAs, small sample
sizes, higher background omega-3 intakes, and the concurrent use of modern pharmaco-
therapy for CVD prevention. At least one of these caveats is being assessed in major clinical
trials, with two omega-3 PUFA pharmacological agents being tested at doses of 4 g/day
(instead of the more common G1 g/day). These null findings, however, do not necessarily
mean that omega-3 PUFAs “are ineffective” in general, only that they were not effective in
the context in which they were tested. Accordingly, higher intakes of omega-3 PUFAs,
either from fatty fish or from supplements, if continued for decades (as the epidemiolog-
ical data support) are likely to contribute towards lower risk for CVD. At this time, evidence
supports the consumption of a healthy dietary pattern with at least two servings per week
of fatty fish. Omega-3 PUFA supplementation is a reasonable alternative for those who do
not consume fish, although fish is the preferred source of omega-3 PUFAs because it also
provides additional nutrients, some of which are often under-consumed.
Introduction
The relationship between marine-derived omega-3
polyunsaturated fatty acids (PUFAs) and cardiovascu-
lar disease (CVD) originated from the early studies of
Greenland’s Inuit population, an isolated cohort with
a low incidence of ischemic heart disease and a die-
tary pattern comprised primarily of whales, seals, sea
birds, and fish [1, 2]. Compared to a Danish cohort,
this unique population had a less atherogenic lipid
profile, lower platelet counts, higher omega-3 PUFAs
in platelet membranes, and longer blood clotting
times. It was hypothesized that the low incidence of
CVD and reduced risk profile was a consequence of
the antithrombotic effects of the distinct dietary pat-
tern, high in the marine-derived omega-3 PUFAs
eicosapentaenoic acid (EPA) and docosahexaenoic ac-
id (DHA). These seminal findings were the basis for
over four decades of observational and intervention
studies conducted to evaluate the relationship be-
tween omega-3 PUFAs and CVD risk factors and
events.
The preponderance of evidence from secondary
prevention trials in the 1980s through the early
2000s demonstrated a cardioprotective effect of fish
consumption and omega-3 PUFA supplementation
[3–7]. Similarly, meta-analyses of observational
studies reported an inverse relationship between
fish consumption and fatal coronary heart disease
(CHD) [8–10]. The growing evidence base led to
seafood/fish and omega-3 PUFA intake recommen-
dations from leading organizations, as well as a
qualified health claim from the Food and Drug
Administration (FDA) (issued in 2004): “Support-
ive but not conclusive research shows that con-
sumption of EPA and DHA omega-3 fatty acids
may reduce the risk of coronary heart disease.
One serving of [Name of the food] provides []
gram of EPA and DHA omega-3 fatty acids [11].”
Data from recent prospective studies show an
inverse relationship between biomarkers of
marine-derived fatty acids, an objective measure of
omega-3 PUFA consumption, and coronary out-
comes [12, 13•]. A meta-analysis of 19 observa-
tional studies (n = 45,637) and fatty acid bio-
markers (total plasma, phospholipids, cholesterol
esters, and adipose tissue) using a continuous
(per 1-SD increase) multivariable-adjusted analysis
reported that EPA, docosapentaenoic acid (DPA),
and DHA were associated with a 9–10 % lower
risk of fatal CHD [RRs of 0.91 (95 % CI, 0.82–
1.00) for EPA, 0.90 (95 % CI, 0.85–0.96) for DPA,
and 0.90 (95 % CI, 0.84–0.96) for DHA] [13•]. In
addition, the sum of EPA, DPA, and DHA was
associated with an 11 % lower risk of fatal CHD
(RR 0.89; 95 % CI, 0.84–0.95). A 2016 analysis of
two prospective cohort studies, the Nurses’ Health
Study (n = 83,349) and Health Professionals
Follow-up Study (n = 42,884), found that intake of
marine-derived omega-3 PUFAs was associated with
lower total mortality when comparing extreme
quintiles of intake (HR 0.96; 95 % CI, 0.93–1.00;
p = 0.002 for trend) [14•].
In contrast to the collective observational evi-
dence and early intervention trials, recent clinical
trials have not reported beneficial effects of omega-
3 PUFA supplementation on CVD outcomes [15–
18, 19••]. Experts at the International Society for
the Study of Fatty Acids and Lipids discussed ex-
perimental design issues that may be responsible
for the null findings in recent investigations and
must be considered in future clinical designs, such
as an overshadowing effect of current CVD treat-
ment on omega-3 PUFA benefits, high background
intakes, small sample sizes, short treatment dura-
tion, insufficient dosage, increase in omega-6 PUFA
intake, and failure to measure baseline omega-3
status [20•]. In 2016, the Agency for Healthcare
Research and Quality published a systematic review
of 61 randomized clinical trials (RCTs) and 37
longitudinal observational studies of omega-3
PUFAs and CVD risk factors or outcomes [21••].
The authors concluded there is high strength of
evidence that increased marine oil intake improves
high-density lipoprotein cholesterol (HDL-C)
(0.9 mg/dL; 95 % CI, 0.2, 1.6), triglycerides
(−24 mg/dL; 95 % CI, −31, −18), and the total
cholesterol to HDL-C ratio (−0.17; 95 % CI,
−0.26, −0.09), but does not affect risk of major
adverse cardiovascular events, all-cause mortality,
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sudden cardiac death, coronary revascularization, or
blood pressure. Notably, there is also high strength
of evidence of increased intake and increased low-
density lipoprotein cholesterol (LDL-C) (2.0 mg/dL;
95 % CI, 0.4, 3.6).
The divergent findings from the recent clinical
trials (versus the earlier trials) have ignited debate
and confusion about the relationship between
omega-3 PUFAs and CVD outcomes. This paper
summarizes the scientific evidence from key early
RCTs that were the impetus for subsequent trials,
reviews RCTs published in the last 6 years, and
presents potential explanations for the discrepant
results. A fatty acid primer, dietary sources of
marine-derived omega-3 fatty acids, intake recom-
mendations, and ongoing trials are discussed.
Omega-3 fatty acid structure and physiological effects
& Structurally, fatty acids consist of a hydrocarbon chain with a car-
boxyl group (C(O)OH) and a methyl group (CH3) at opposing
ends [22]. The absence of a double bond within the hydrocarbon
chain denotes a saturated fatty acid, while the presence of one or
more double bonds is characteristic of an unsaturated fatty acid.
There are two types of unsaturated fatty acids, monounsaturated
fatty acids containing one double bond and PUFAs containing two
or more double bonds. Common convention describes unsaturated
fatty acids based on the position of the first double bond relative to
the methyl terminus carbon (“ω” or “n”). There are two subclasses
of PUFAs, omega-3 and omega-6 fatty acids. Omega-3 fatty acids
contain the first double bond between the third and fourth carbons
from the methyl terminus and are classified as long chain fatty
acids due to the carbon chain length.
& Omega-3 fatty acids of significance in human physiology and nutrition are
α-linolenic acid (ALA; 18:3), EPA (20:5), and DHA (22:6) [22]. ALA is an
essential fatty acid; it cannot be synthesized in humans and, thus, must be
obtained through plant-based sources such as flaxseeds, walnuts, and
canola oil. EPA and DHA are considered non-essential, as they can be
synthesized from ALA via a series of desaturation and chain elongation
steps. However, this pathway is inefficient, with human isotope studies
reporting G0.1–7.9 % of ALA converted to EPA and G0.1–3.8 % of ALA
converted to DHA [23]. Therefore, intake of marine-derived EPA and DHA
is crucial for beneficial health effects.
& Mozaffarian and Wu reviewed the physiological effects of seafood-
derived omega-3 PUFAs relative to cardiovascular health [24].
Omega-3 PUFAs have been shown in clinical settings to reduce
triglycerides, blood pressure, and resting heart rate and improve
endothelial dysfunction. Growing evidence suggests that omega-3
PUFAs may also reduce systemic vascular resistance and arrhythmias
and improve myocardial efficiency and left ventricular diastolic
filling. Antithrombotic properties have been suggested; however, the
effect may only be apparent at very high doses (e.g., 15 g/day). In
addition, omega-3 PUFA metabolites have anti-inflammatory effects,
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but the clinical relevance at dietary doses requires further
investigation.
Dietary sources and recommend intakes of EPA and DHA
& Fatty fish and seafood are the principal dietary sources of EPA and
DHA (Table 1). Both wild and farm-raised varieties provide EPA
and DHA, and some evidence suggests the latter may contain
greater concentrations [27••]. In addition to their favorable fatty
acid profiles, oily fish and seafood are nutrient dense dietary
choices that are high in protein, low in saturated fat, and contain
micronutrients (many of which are under-consumed), such as vita-
min D, vitamin B12, selenium, potassium, and magnesium [28•]
(Table 1). Higher trophic fatty fish (e.g., tilefish, king mackerel,
shark, and swordfish) may be contaminated with methyl mercury or
organic pollutants and should be avoided by vulnerable popula-
tions, particularly pregnant or breastfeeding women, those who may
become pregnant, and children [26, 27••, 29••].
& Krill, cod liver, and algal oils are non-traditional marine sources of long
chain omega-3 fatty acids that have garnered attention as an alternative
source of EPA and DHA. Future research is needed, however, to assess the
health benefits of these oils.
& EPA and DHA are also available in omega-3 fortified foods, in-
cluding breads, pastas, cereals, dairy products, eggs, meats, juices,
salad dressings, spreads, and oils [30]. This is a result of fish oils
(e.g., menhaden, salmon, tuna, anchovy) and algal oils directly
added to foods, or animals given feed containing EPA and/or DHA
to enrich their tissues. Consumption of omega-3 fortified foods is a
potential option to increase EPA and DHA intake in vegans, vege-
tarians, or individuals who dislike fish/seafood.
& Leading dietary and cardiovascular health organizations issued in-
take recommendations for seafood/fish and marine-derived long
chain fatty acids (Table 2). Notably, the FDA approved up to
3000 mg/day of EPA plus DHA from food and supplements as safe
for the general population [36].
Timeline of early primary and secondary prevention trials
1980s
& The Diet and Reinfarction Trial (DART), published in 1989, was
the first RCT to assess secondary prevention of myocardial in-
farction (MI) with dietary advice in 2,033 men recovered from
previous MI [3]. The intervention group advised to consume ≥2
servings (200–400 g) of fatty fish per week had a 29 % reduc-
tion in risk of all-cause mortality (RR 0.71; 95 % CI, 0.54–0.93;
p G 0.05) at 2 years versus the no advice control. A subset of
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participants who could not tolerate fish were given fish oil capsules
(Maxepa 3 g/day); subgroup analyses indicated the effect of capsules
was similar to the fatty fish treatment group [37].
1990s
& The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
micardico Prevenzione (GISSI-Prevention) secondary prevention study
included 11,323 participants (14.7 % female) with previous MI
(≤3 months) and compared one fish oil capsule per day (850–882 mg
EPA plusDHA as ethyl esters) in combinationwith the current standard
of care versus standard of care alone for 3.5 years [4, 5]. Time course
analyses revealed early effects of combination therapy; at 3months, the
intervention group had a 41 % reduction in risk of all-cause mortality
(RR 0.59; 95 % CI, 0.36–0.97; p = 0.037) and, at 4 months, a 53 %
reduction in risk of sudden cardiac death (RR 0.47; 95%CI, 0.22–0.99;
p = 0.048) [5]. At study completion, the reductions in risk of total death
(RR 0.79; 95 % CI, 0.66–0.93; p = 0.006) and sudden death (RR 0.55;
95 % CI, 0.39–0.77; p = 0.0006) remained significant. The authors
concluded the lowered risk of all-cause mortality was driven primarily
by the reduction in sudden cardiac death and hypothesized an antiar-
rhythmic effect of EPA and DHA.
Table 2. Recommended intakes of seafood/fish and marine-derived long chain fatty acids
Organization Population Recommendation
Academy of Nutrition and
Dietetics [31•]
Healthy adults Two or more servings of fatty fish per week,




All adults Fish (particularly fatty) at least twice a week
Patients with documented coronary
heart disease
∼1 g of EPA and DHA (combined) per daya
Patients with hypertriglyceridemia 2–4 g of EPA plus DHA per day provided as capsules
under a physician’s care
Women with hypercholesterolemia
and/or hypertriglyceridemia
Omega-3 fatty acids in the form of fish or capsule
(e.g., EPA 1800 mg/day) may be considered
U.S. Department of
Agriculture, U.S.
Department of Health and
Human Services [29••]
General population 8 oz. per week of a variety of seafood, providing an
average of 250 mg per day of EPA and DHA




Adults ≥2 servings (3.5–4 oz.) of fish/seafood
(preferably oily) per weekc
EPA eicosapentaenoic acid, DHA docosahexaenoic acid
aPreferably from the consumption of oily fish; omega-3 fatty acid capsules can be considered in consultation with a physician
bChoose sources high in DHA and low in methyl mercury to optimize infant health outcomes
cShould not be prepared using deep-frying methods
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2000s
& The Diet And Reinfarction Trial 2 (DART-2) was a secondary
prevention trial conducted in men with stable angina, rather than
previous MI as was done in DART-1 [38]. Participants (n = 3,114)
advised to eat two portions of oily fish per week (or 3 g/day of
fish oil capsules) had a higher risk of cardiac death (HR 1.26;
95 % CI, 1.00–1.58; p = 0.047) and sudden cardiac death (HR 1.54;
95 % CI, 1.06–2.23; p = 0.025) at 3–9 years of follow-up versus the
control of non-specific, sensible eating advice. Subgroup analyses
revealed these results were driven by the fish oil capsule group (n =
462), not the dietary fish advice group (n = 1,106), as evident by a
higher risk of cardiac death (HR 1.45; 95 % CI, 1.05–1.99; p =
0.024) and sudden cardiac death (HR 1.84; 95 % CI, 1.11–3.05;
p = 0.018) in capsule compared to controls. However, the quality of
DART-2 and its experimental design limitations, such as lack of
blinding, study interruption at 1 year, assessment of compliance
from a small subset, and similarities in background fish consump-
tion between treatment and control, have been criticized [39].
& Investigators in Japan evaluated the effects of statin plus
1800 mg EPA daily versus statin alone in the Japan EPA Lipid
Intervention Study (JELIS) [6]. This combined primary (n =
14,981) and secondary intervention (n = 3,664) trial followed
participants (69 % female) a mean 4.6 years and reported the
statin with EPA cohort had a 19 % reduction in major coronary
events (HR 0.81; 95 % CI, 0.69–0.95; p = 0.011). Subgroup
analyses revealed those with a history of coronary artery disease
(defined as MI 9 6 months, coronary interventions, or stable
angina pectoris) had a 19 % reduction in major coronary events
(HR 0.81; 95 % CI, 0.66–1.00; p = 0.048), while those without a
history of coronary artery disease did not have a significant
reduction in major coronary events (HR 0.82; 95 % CI, 0.63–
1.06; p = 0.132). The null findings in the primary prevention
group were attributed to a lack of power to detect significance.
Notably, the risk of sudden cardiac death did not differ between
treatment and control in the combined (p = 0.854) and subgroup
analyses (primary p = 0.736, secondary p = 0.967).
& GISSI-Heart Failure (GISSI-HF) was the first large, randomized,
double-blind, placebo-controlled trial conducted to assess the
efficacy of omega-3 fatty acids (850–882 mg EPA plus DHA as
ethyl esters) versus placebo in men and women with chronic
heart failure (n = 6,975) [7]. At a median 3.9 years of follow-up,
patients in the omega-3 group had a 9 % reduction in all-cause
mortality (HR 0.91; 95.5 % CI, 0.833–0.998; p = 0.041) and an
8 % reduction in cardiovascular hospital admissions (HR 0.92;
99 % CI, 0.849–0.999; p = 0.009) compared to placebo. This
moderate reduction in events with EPA plus DHA was observed
in the context of standard of care practices in the early 2000s.
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Recent RCTs (2010–2016)
Alpha Omega (2010)
& The Alpha Omega trial was a double-blind, placebo-controlled, ran-
domized, secondary prevention study in patients with a MI in the past
10 years (median 3.7 years) [15]. In contrast with previous study
interventions, this trial provided low dose omega-3 fatty acids or
placebo in margarine for daily consumption for 40 months.
& Patients in the EPA plus DHA arms consumed 18.8 g/day of margarine
containing 226 mg EPA and 150 mg DHA. The study sample (n = 4,837)
was primarily oldermen (78%men;mean age = 69 years) with almost all
participants receiving therapies at baseline (antithrombotic (97.5 %),
antihypertensive (89.7 %), and lipid modifying (86 %)). After a median
follow-up of 40.8 months, the EPA plus DHA containing margarines did
not reduce the rate of major cardiovascular events (composite of fatal and
non-fatal cardiovascular events and cardiac interventions) compared to
non-EPA and DHAmargarines (336 (14 %) vs. 335 (13.8 %)) (HR 1.01;
95 % CI, 0.87–1.17; p = 0.93). All secondary a priori outcomes were null.
& Both GISSI-Prevention [4, 5] and Alpha Omega were secondary
prevention trials of omega-3 fatty acids conducted for approxi-
mately 3.5 years in primarily male patients with previous MI. There
are notable differences between the trials; GISSI-Prevention pro-
vided roughly double the dose of EPA and DHA, had a significantly
larger sample size, delivered the intervention in oral supplement
form, included higher risk patients with recent MI (median
16 days), had a younger sample (mean age at baseline 59.3 years),
and followed standard of care practices from the 1990s (e.g., 4.7 %
of patients on cholesterol-lowering therapies at baseline and 45.5 %
at end of study) [4, 5]. JELIS was comparable to Alpha Omega in
medication use (100 % of JELIS participants prescribed statins) and
sample size in the secondary prevention cohort; however, the dif-
fering outcomes may be attributed to the eight times higher dose of
EPA in JELIS provided to a primarily female, younger cohort (mean
age at baseline 61 years) for a longer duration [6]. In addition, the
Alpha Omega comparison group for statistical analyses was not a
true placebo, but rather a composite of placebo or ALA-containing
margarines.
OMEGA (2010)
& The purpose of OMEGA was to evaluate the addition of omega-3
PUFA supplementation to current guideline-adjusted therapy on
the prognosis of recent MI survivors (3–14 days) [16]. This
randomized, placebo-controlled, double-blind trial compared
1 g/day of omega-3 capsules (460 mg EPA and 380 mg DHA as
Curr Treat Options Cardio Med (2016) 18: 69 Page 9 of 16 69
ethyl esters-90) versus 1 g/day of olive oil control in the context
of current treatment.
& The investigators enrolled 3,851 patients (74.4 % male; median age
64 years). At 1 year of follow-up, event rates for all outcomes did not
differ between the intervention and control groups, including sudden
cardiac death (p = 0.84), all-cause mortality (p = 0.18), major adverse
cerebrovascular or cardiovascular events (p = 0.1), and revasculariza-
tion (p = 0.34).
& The lack of significant findings was likely the result of an underpowered
study; the authors acknowledged they did not reach 80 % statistical
power and, after revised calculations, would require a sample size of
20,000 to detect a significant effect. This was due to an over estimation
of the effect of omega-3 fatty acids, as well as the lower than expected
event rates (e.g., totalmortality and sudden cardiac death), indicative of
improved clinical care. In addition, both groups increased their fish
consumption from baseline to study completion, potentially causing
comparable total omega-3 PUFA intakes between groups. Moreover,
the study duration of a 1-year supplementation period and follow-up
may not have been sufficient.
SU.FOL.OM3 (2010)
& Supplémentation en Folates et Omega-3 (SU.FOL.OM3) was a double-
blind, randomized, placebo-controlled, 2 × 2 factorial trial of B vitamin
supplementation (560 μg 5-methyltetrahydrofolate, B6, and B12) or
placebo and omega-3 fatty acids (600mg EPA and DHA) or placebo in
patients with an acute coronary (MI or acute coronary syndrome) or
cerebral ischemic event in the past 12 months [17].
& At baseline, the median time from event to randomization for all study
participants (n = 2,501) was 101 days. During a median follow-up of
4.7 years, omega-3 fatty acids did not significantly reduce major vas-
cular events (composite of non-fatal MI, stroke, or death from CVD)
(81 (6.5%) vs. 76 (6.1%)) (HR 1.08; 95%CI, 0.79–1.47; p = 0.64). All
secondary outcomes were not significantly different between omega-3
supplementation and placebo.
& SU.FOL.OM3 was underpowered due to a 15% lower than anticipated
event rate; standard of care pharmacotherapy practices were prevalent
(e.g., 93 % using Aspirin/anti-platelet therapy, 85 % using lipid low-
ering agents) and likely contributed to the low event rate. Additionally,
the interval from initial event to omega-3 supplementation may have
been too lengthy; the beneficial effects of omega-3 fatty acids may be
more discernable in the acute phase.
ORIGIN (2012)
& The Outcome Reduction with an Initial Glargine Intervention
(ORIGIN) trial was the first large study to investigate the efficacy of
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long-term omega-3 fatty acid supplementation on cardiovascular
events in individuals with CVD plus impaired glucose tolerance, im-
paired fasting glucose, or diabetes [18]. This trial was a double-blind,
randomized, placebo-controlled, 2 × 2 factorial design of 1 g/day of
fish oil (465 mg EPA and 375 mg DHA as ethyl esters) versus 1 g/day
olive oil placebo and insulin glargine versus standard care.
& The investigators followed 12,536 patients for a median of 6.2 years
and reported the primary outcome of death from cardiovascular causes
was not significantly decreased in the omega-3 group compared to
placebo (574 (9.1 %) vs. 581(9.3 %)) (HR 0.98; 95 % CI, 0.87–1.10;
p = 0.72). In addition, all other study outcomes, including rates of
major vascular events (MI, stroke, death from cardiovascular causes),
all-cause mortality, and death from arrhythmia, were not significantly
reduced in the omega-3 group versus placebo.
& The ORIGIN findings are in contrast with the GISSI-Prevention and
GISSI-HF results, despite comparable supplement dose and fatty acid
form across studies. The differing populations for secondary prevention
may explain this discrepancy: GISSI-Prevention patients had aMI in the
past 3 months (median 16 days) [4, 5], GISSI-HF patients had chronic
heart failure [7], andORIGIN patients had dysglycemia and evidence of
CVDwithmore inclusive criteria. Another potential explanation for the
lack of significant findings is the use of concomitant therapies among
the ORIGIN population, thereby preventing a detectable effect of low
dose omega-3 supplementation. Higher doses may be necessary with
advanced medical care.
Risk and Prevention (2013)
& The Risk and Prevention study was a randomized, double-blind,
placebo-controlled trial that assessed the efficacy of 1 g/day of omega-3
fatty acids (850–882 mg EPA and DHA as ethyl esters) versus olive oil
placebo in an Italian cohort of patients at high CVD risk without
previous MI [19••, 40]. Both arms included standard of care treatment
and preventive strategies, such as lifestyle interventions and pharma-
cological therapies. The primary endpoint was originally the cumula-
tive rate of death, non-fatal MI, and non-fatal stroke; however, follow-
ing intermediate blinded analyses that revealed low event rates, the
primary endpoint was changed to the composite of death or hospital-
ization from cardiovascular cause [19••].
& The investigators enrolled 12,513 patients with a median follow-up
of 5 years. Intent to treat analyses (n = 12,505) showed the primary
endpoint was not significantly reduced in the omega-3 group
compared to placebo (733 (11.7 %) vs. 745 (11.9 %)) (HR 0.98;
95 % CI, 0.88–1.08; p = 0.64) and the secondary endpoints were
null. Subgroup analyses revealed significantly fewer heart failure
hospitalizations in the omega-3 group (96 (1.5 %) vs. 142
(2.3 %); p = 0.002) and women in the omega-3 group had lower
Curr Treat Options Cardio Med (2016) 18: 69 Page 11 of 16 69
rates of the primary endpoint (187 (8 %) vs. 237 (9.6 %)) (HR
0.82; 95 % CI, 0.67–0.99; p = 0.04).
& The authors acknowledged the lower than expected rates of hard car-
diovascular endpoints as a trial limitation. This may be a consequence
of inclusion of an Italian cohort following a Mediterranean dietary
pattern and/or effective preventive standard of care practices. Similar to
theOMEGA [16] andORIGIN trials [18], the Risk and Prevention study
used olive oil as the placebo. In the PREDIMED (Prevención con Dieta
Mediterránea) trial, a Mediterranean diet supplemented with extra-
virgin olive oil (50 g/day) reduced the incidence of major cardiovas-
cular events (composite of myocardial infarction, stroke, or death from
cardiovascular cause) at 5 years of follow-up [41]. The reduction in
major cardiovascular events may have been a result of the Mediterra-
nean dietary pattern, the olive oil, or a combined effect. If olive oil
alone is responsible for the observed benefits, it may not be an appro-
priate control in omega-3 fatty acid trials; however, low dose olive oil
(i.e., 1 g/day) is unlikely to affect cardiovascular outcomes.
Ongoing clinical trials
& Four ongoing studies will provide further evidence of the efficacy of
omega-3 supplementation in both generally healthy, low-risk groups, as
well as high-risk populations. Below are summaries of the study designs,
target populations, primary outcomes, and expected completion dates.
The results of these CVD prevention trials are expected to be available in
2018–2019.
& A Study of Cardiovascular Events in Diabetes (ASCEND) is a randomized,
placebo-controlled, double-blind, 2 × 2 factorial trial of 100 mg/day aspi-
rin or placebo and 1 g/day omega-3 fatty acids (400mg EPA plus 300DHA
as ethyl esters) or olive oil placebo in 15,480 patients ≥40 years with
diabetes (type 1 or 2) and without a history of vascular disease [42, 43].
Participants in this primary prevention trial will be followed on average 5–
7 years for serious vascular events (defined as non-fatalMI, non-fatal stroke
or transient ischemic attack, or vascular death excluding cerebral hemor-
rhage). The study began in 2004 and the estimated completion date is
September 2017 (ClinicalTrials.gov Identifier NCT00135226).
& The Vitamin D and Omega-3 Trial (VITAL) is the first trial of omega-3
supplements for the primary prevention of cancer and CVD in the
general population without cancer or CVD at baseline [44, 45]. VITAL
is a randomized, double-blind, placebo-controlled, 2 × 2 factorial study
of vitamin D3 (2000 IU/d) versus placebo and 1 g/day Omacor fish
oil supplement (465 mg EPA plus 375 mg DHA) versus placebo. The
primary outcome is risk of total cancer and major CVD events (MI,
stroke, cardiovascular mortality). Enrollment and randomization began
in November 2011 and was completed in March 2014, with a total
sample size of 25,875 males (≥50 years) and females (≥55 years) and
an over sampling of blacks [46]. The mean follow-up is a predicted
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5 years and the estimated completion date is December 2017
(ClinicalTrials.gov Identifier NCT01169259).
& The Reduction of Cardiovascular Events with EPA-Intervention Trial
(REDUCE-IT) is a randomized, parallel arm, double-blind trial to compare
4 g/day of Vascepa (EPA ethyl ester) with statin therapy versus statin
therapy alone in reducing cardiovascular events (composite of cardiovas-
cular death, MI, stroke, coronary revascularization, and hospitalization for
angina) [47, 48]. This is the first study to assess high dose EPA plus statin in
a Western population with hypertriglyceridemia despite statin use. Eligi-
bility criteria include hypertriglyceridemia, established CVD or high risk
for CVD, and aged ≥45 years. A predicted 8,000 participants will be
followed for 4–6 years. The trial commenced in 2011 and the estimated
completion is 2017, with results available in 2018 (ClinicalTrials.gov
Identifier NCT01492361).
& STRENGTH (Statin Residual Risk Reduction with Epanova in High Risk
Patients with Hypertriglyceridemia) is a randomized, double-blind, par-
allel arm, placebo-controlled trial of 4 g/day Epanova (omega-3 carboxylic
acids) plus statin versus corn oil placebo plus statin [49]. Participants
(target n = 13,000) 18–99 years with optimal LDL-C levels, hypertriglyc-
eridemia, low HDL-C, and high CVD risk will be followed 3–5 years for
major atherosclerotic coronary events (composite of cardiovascular death,
non-fatal MI or stroke, coronary revascularization, or angina hospitaliza-
tion). Study enrollment began in 2014 and the anticipated study comple-
tion date is 2019 (ClinicalTrials.gov Identifier NCT02104817).
Conclusions
Results from early trials of fish consumption and omega-3 PUFA supple-
mentation, as well the collective observational data, demonstrate a
cardioprotective effect of long chain omega-3 fatty acids. In contrast, primary
and secondary prevention trials published in the last 6 years report null
effects of supplementation and call in to question the efficacy of low dose
omega-3 PUFAs in reducing cardiovascular events. Potential explanations for
the discrepant results include underpowered studies with small samples and
low event rates, participants with high background fish/seafood intakes,
suboptimal EPA and DHA dosage, supplementation duration, age at study
enrollment, length of follow-up, and concurrent standard of care for CVD
treatment. Notably, supplementation of 1 g/day of EPA plus DHA is unlikely
to affect CVD outcomes in the context of modern CVD treatment with
multiple pharmacotherapies. Four ongoing trials address numerous design
limitations, and their results will provide crucial insight into the effects of
EPA and DHA supplementation on CVD outcomes.
Based on the available evidence, physicians should advise patients to
consume a healthy dietary pattern that includes at least two servings of fatty
fish per week. This is an important adjunct to the standard of care for CVD
treatment. For individuals who do not consume omega-3 rich fish, fish oil
capsules as a source of EPA and DHA need not be discouraged, given their
long safety record and the benefit to risk ratio; however, LDL-C levels should
be monitored, especially in hypertriglyceridemic patients being treated with
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high doses of omega-3 fatty acids. Nevertheless, a food-based approach is the
preferred option to deliver not only the marine-derived omega-3 PUFAs EPA
and DHA, but also other beneficial nutrients.
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